[1] TSAI C H,HILL M,ASA S L,et al.Intestinal growth-promoting properties of glucagon-like peptide 2 in mice[J].American Journal of Physiology:Endocrinology and Metabolism,1997,273(1 Pt 1):E77-E84.
[2] WOJDEMANN M,WETTERGREN A,HARTMANN B,et al.Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide 2[J].The Journal of Clinical Endocrinology & Metabolism,1999,84(7):2513-2517.
[3] BENJAMIN M A,MCKAY D M,YANG P C,et al.Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse[J].Gut,2000,47(1):112-119.
[4] GUAN X,STOLL B,LU X,et al.GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets[J].Gastroenterology,2003,125(1):136-147.
[5] PEDERSEN N B,HJOLLUND K R,JOHNSEN A H,et al.Porcine glucagon-like peptide-2:structure,signaling,metabolism and effects[J].Regulotary Peptides,2008,146(1/2/3):310-320.
[6] BURRIN D G,STOLL B,GUAN X.Glucagon-like peptide 2 function in domestic animals[J].Domestic Animal Endocrinology,2003,24(2):103-122.
[7] LEE S H,LEE S,YUS Y,et al.Synthesis,characterization,and pharmacokinetic studies of PEGylated glucagon-like peptide-1[J].Bioconjugate Chemistry,2005,16(2):377-382.
[8] QI K K,WU J,WAN J,et al.Purified PEGylated porcine glucagon-like peptide-2 reduces the severity of colonic injury in a murine model of experimental colitis[J].Peptide,2014,52(2):11-18.
[9] OHKUSA T.Production of experimental ulcerative colitis in hamsters by dextran sulfate sodium and changes in intestinal microflora[J].Japanese Journal of Gastroenterology,1985,82(5):1327-1336.
[10] 温红珠,郝薇薇,李佳,等.葡聚糖硫酸钠结肠炎模型影响因素的研究进展[J].世界华人消化杂志,2011,19(36):3666-3671.
[11] YAN Y,KOLACHALA V,DALMASSO G,et al.Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis[J].PLoS One,2009,4(6):e6073.
[12] MENNIGEN R,NOLTE K,RIJCKEN E,et al.Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis[J].American Journal of Physiology,2009,296(5):G1140-G1149.
[13] PORITZ L S,GARVER K I,GREEN C,et al.Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis[J].Journal of Surgical Research,2007,140(1):12-19.
[14] PORITZ L S,HARRIS L R,KELLY A A,et al.Increase in the tight junction protein claudin-1 in intestinal inflammation[J].Digestive Diseases and Sciences,2011,56(10):2802-2809.
[15] DRUCKER D J,EHRLICH P,ASA S L,et al.Induction of intestinal epithelial proliferation by glucagons-like peptide 2[J].Proceedings of the National Academy of Sciences of the United States of America,1996,93(15):7911-7916.
[16] BOUSHEY R P,YUSTA B,DRUCKER D J.Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis[J].American Journal of Physiology- Endocrinology and Metabolism,1999,277(5 Pt 1):E937-E947.
[17] DRUCKER D J,YUSTA B,BOUSHEY R P,et al.Human GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis[J].American Journal of Physiology-Gastrointestinal and Liver Physiology,1999,276(1 Pt 1):G79-G91.
[18] ALAVI K,SCHWARTZ M Z,PALAZZO J P,et al.Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2[J].Journal of Pediatric Surgery,2000,35(6):847-851.
[19] VERONESE F M,PASUT G.PEGylation,successful approach to drug delivery[J].Drug Discovery Today,2005,10(21):1451-1458.
[20] FEE C J,VAN ALSTINE J M.PEG-proteins:reaction engineering and separation issues[J].Chemical Engineering Science,2006,61(3):924-939.
